Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open Label, Phase II Study of OSI-7904L Versus 5-FU/LV as First-Line Treatment in Patients With Unresectable, Locally Advanced or Metastatic Adenocarcinoma of the Biliary Tract

NCT00088270 is registered in ClinicalTrials.gov with OSI Pharmaceuticals as lead sponsor.

NCT NCT00088270
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00088270 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open Label, Phase II Study of OSI-7904L Versus 5-FU/LV as First-Line Treatment in Patients With Unresectable, Locally Advanced or Metastatic Adenocarcinoma of the Biliary Tract
Lead sponsor
OSI Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2004
Completion date
August 31, 2005
Enrollment
58
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced or metastatic adenoca of the biliary tract